Earnings Review
Alkem Labs' consol PAT up 4% on yr, but misses Street view
This story was originally published at 16:51 IST on 29 May 2025
Register to read our real-time news.Informist, Thursday, May 29, 2025
Please click here to read all liners published on this story
--Alkem Lab Jan-Mar consol PAT INR 3.06 bln
--Analysts saw Alkem Lab Jan-Mar consol net profit INR 3.56 bln
--Alkem Lab Jan-Mar consol PAT INR 3.06 bln vs INR 2.94 bln year ago
--Alkem Lab Jan-Mar consol revenue INR 31.44 bln vs INR 29.36 bln year ago
--Alkem Lab to pay INR 8 per share final dividend; record date Aug 8
--Alkem Lab FY25 consol net profit INR 21.65 bln vs INR 17.96 bln year ago
--Alkem Lab FY25 consol revenue INR 129.65 bln vs INR 126.68 bln year ago
--Alkem Lab Jan-Mar consol EBITDA INR 3.91 bln vs INR 4.02 bln year ago
--Alkem Lab FY25 consol EBITDA INR 25.12 bln vs INR 22.46 bln year ago
--Alkem Lab Jan-Mar consol EBITDA margin 12.4% vs 13.7% year ago
--Alkem Lab FY25 consol EBITDA margin 19.4% vs 17.7% year ago
--Alkem Lab Jan-Mar India revenue INR 21.36 bln, up 8.1% on year
--Alkem Lab Jan-Mar intl revenue INR 9.75 bln, up 7.2% on year
--Alkem Lab Jan-Mar US revenue INR 6.09 bln, down 2.5% on year
--Alkem Lab Jan-Mar consol gross margin 59.3% vs 62.3% year ago
By P. Madhu Kumar
MUMBAI – Alkem Laboratories Ltd. reported a 4% on-year rise in its consolidated net profit to INR 3.06 billion for the March quarter but slightly missed the Street estimates. The company's revenue rose over 7% on year to INR 31.44 billlon for the latest quarter, driven by growth in domestic sales. The surge in its top line and bottom line was also supported by a decline in other expenses of the company.
Domestic sales accounted for 69% of the total sales in Jan-Mar and rose over 8% on year to INR 21.36 billion, while the share of international business went up just over 7% to INR 9.75 billion. US sales was the only segment where the company saw downfall, as it declined 2.5% on year to INR 6.09 billion.
The pharmaceutical major's consolidated earnings before interest, tax, depreciation, and amortisation in the March quarter was INR 3.91 billion as compared to INR 4.02 billion in the year-ago perios. EBITDA margin for the reporting quarter contracted to 12.4% from 13.7% in the year ago period.
A surge in Alkem lab's top line was also seen as its other expenses fell nearly 7% on year to INR 8.57 billion for the March quarter. A slight drop of nearly 3% was also seen in the cost of materials consumed, which fell to INR 7.77 billion for the same period. Total expenses increased over 9% on year to INR 28.93 billion for the March quarter. The company's consolidated gross margin for the March quarter stood at 59.3% as compared to the 62.3% from the year-ago period.
In FY25, the company reported a growth of over 20% in its bottom line to INR 21.65 billion from INR 17.96 billion in the year ago period. The top line for the year rose over 2% to INR 129.65 billion. The EBITDA margin for the full year was 19.4% as compared to 17.7% year ago. The company's EBITDA for the same period grew nearly 11% to INR 25.12 billion.
Alkem Labs' board decided to pay a final dividend of INR 8 per equity share for the full year with a record date set on Aug. 8. On Thursday, shares of Alkem Laboratories closed 0.6% up at INR 5294.50 on the National Stock Exchange. End
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Edited by Tanima Banerjee
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
